Larisa Cavallari
Professor
- Gainesville FL UNITED STATES
- College of Pharmacy
Larisa Cavallari's research involves discovery and clinical translation of genetic variants related to drug response.
Contact More Open optionsBiography
Larisa Cavallari is a professor and the Debbie DeSantis Term Professor in the Department of Pharmacotherapy & Translational Research. She serves as director of the Center for Pharmacogenomics and Precision Medicine and director of the UF Health Precision Medicine Program. Larisa's research involves discovery and clinical translation of genetic variants related to drug response.
Areas of Expertise
Media Appearances
UF researchers awarded $3.5 million grant to study outcomes using genetic information to guide blood thinning therapy
UF Health online
2020-07-13
Researchers at the University of Florida have received a $3.5 million grant from the National Heart, Lung and Blood Institute, or NHLBI, to study the effect of using genetic information to guide therapy after an angioplasty heart procedure to prevent heart attacks and strokes.
Clinical Analytics Studies, Partnerships Target Personalized Care
Health IT Analytics online
2016-11-17
From tailored therapies based on precision medicine techniques to individualized chronic disease management and mental healthcare, personalization is becoming a major focus for clinical analytics experts looking to maximize positive outcomes.
‘Personalized medicine’ drives better outcomes for certain heart patients
The Business Report online
2015-12-20
In the weeks and months after a patient gets a heart stent, blood clots can pose a major threat to recovery. Now, University of Florida Health researchers have found that a quick genetic test can tell doctors early on whether a crucial anti-clotting drug will work, they reported today (Nov. 9) at the American Heart Association’s Scientific Sessions in Orlando.
Articles
Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing
Future MedicineAshwini Zolekar, et al.
2022-01-10
We evaluated the clinical acceptance and feasibility of a pharmacist-guided personalized consult service following its transition from a mandatory (mPGx) to optional (oPGx) CYP2C9/VKORC1/CYP4F2 genotyping for warfarin.
Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers
The Pharmacogenomics JournalLeonardo A. Guerra, et al.
2021-10-12
Single nucleotide polymorphisms (SNPs) have been associated with differential beta-blocker (BB) effects on heart rate, blood pressure, and left ventricular ejection fraction in various patient populations. This study aimed to determine if SNPs previously associated with BB response are also associated with differential survival in heart failure (HF) patients receiving BBs.
